ABOUND® - Welcome kit - contains: CONTOUR® NEXT ONE Blood - ASCENSIA DIABETES CARE US INC.

Duns Number:080028910

Device Description: Welcome kit - contains: CONTOUR® NEXT ONE Blood Glucose Monitoring System kit (Primary DI Welcome kit - contains: CONTOUR® NEXT ONE Blood Glucose Monitoring System kit (Primary DI Number 00301939763012), 1 carton of CONTOUR® NEXT ONE Blood Glucose Test Strips (Package DI Number 00301937312212), 100 MICROLET® lancets (provided sterile), recipe cards, activity cards, resistance bands (labeled latex free), relaxation mask.

Want to know more about this Product? Request more information now!


More Product Details

Catalog Number

7750

Brand Name

ABOUND®

Version/Model Number

7750

Device Commercial Distribution Status

In Commercial Distribution

Commercial Distribution End Date

-

Issuing Agency

In GS1

Product Characteristics

MRI safety Status

Labeling does not contain MRI Safety Information

Device required to be labeled as containing natural rubber latex or dry natural rubber (21 CFR 801.437)

-

Device labeled as "Not made with natural rubber latex"

Yes

For Single-Use

-

Prescription Use (Rx)

-

Over the Counter (OTC)

Yes

Kit

-

Combination Product

-

Human Cell, Tissue or Cellular or Tissue-Based Product (HCT/P)

-

FDA Premarket Submission

-

Product Code Details

Product Code

FMK

Product Code Name

Lancet, Blood

Device Record Status

Public Device Record Key

71716812-717e-4394-b402-760179b7e698

Public Version Date

September 02, 2019

Public Version Number

2

DI Record Publish Date

June 06, 2019

Additional Identifiers

Package DI Number

None

Quantity per Package

-

Contains DI Package

-

Package Discontinue Date

-

Package Status

-

Package Type

-

"ASCENSIA DIABETES CARE US INC." Characteristics
Device Class Device Class Description No of Devices
1 A medical device with low to moderate risk that requires general controls 7
2 A medical device with a moderate to high risk that requires special controls. 19
3 A medical device with high risk that requires premarket approval 2